Sanna Bastiano's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Nov 3, 2022
- Accession no.
- 0000899243-22-034883
- Filed
- Nov 3, 2022
- Trade date
- Nov 1-2, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions. Open-market sales total $100.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sanna BastianoCIK 0001829069 | Officer (EVP, Cell & Genetic Therapies) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2022 | Common Stock | FTax withholdingDisposed | −768 | $312.84 | −$240,261.12 | 38,424 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −56 | $310.10F2,F3 | −$17,365.6 | 38,368 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −39 | $311.17F2,F4 | −$12,135.63 | 38,329 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −100 | $312.40F2,F5 | −$31,240 | 38,229 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −81 | $313.37F2,F6 | −$25,382.97 | 38,148 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −12 | $314.43F2,F7 | −$3,773.16 | 38,136 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −10 | $315.68 | −$3,156.8 | 38,126 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −22 | $317.77F2,F8 | −$6,990.94 | 38,104 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 6 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $310.10 (range $309.50 to $310.48).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $311.17 (range $310.51 to $311.45).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $312.40 (range $311.98 to $312.90).
Referenced by the price of 1 transaction in Table I.
- F6
Open market sales reported on this line occurred at a weighted average price of $313.37 (range $312.98 to $313.97).
Referenced by the price of 1 transaction in Table I.
- F7
Open market sales reported on this line occurred at a weighted average price of $314.43 (range $314.42 to $314.48).
Referenced by the price of 1 transaction in Table I.
- F8
Open market sales reported on this line occurred at a weighted average price of $317.77 (range $317.56 to $317.82).
Referenced by the price of 1 transaction in Table I.